Stevanato Group S.p.A. filings document the company’s reporting as a foreign private issuer and its business in drug containment, drug delivery and diagnostic solutions. Form 6-K reports furnish interim financial statements, results press releases, investor presentations and conference call materials covering revenue trends, segment performance, high-value solutions, margins, guidance, capacity expansion and risk disclosures.
Governance filings also include shareholder meeting notices, explanatory reports, sustainability reporting, committee reports, remuneration policy materials, dividend allocation matters and director slate information. These documents describe the company’s financial reporting framework, board and committee processes, shareholder voting matters and public-company disclosures for STVN.
Stevanato Group reported first quarter 2026 results showing steady growth and improved profitability. Revenue rose 10% at constant currency and 7% on a reported basis to €273.6 million, driven by 13% growth in the Biopharmaceutical and Diagnostic Solutions segment, which offset a 31% decline in the Engineering segment. High-value solutions revenue increased 17% to €128.6 million and represented 47% of total revenue, supported by strong demand for pre-fillable syringes and GLP1-related volumes, which accounted for about 21% to 22% of company revenue. Gross margin improved to 27.5%, operating margin to 14.2%, and adjusted EBITDA rose 14% to €65.5 million with a 23.9% margin. Net profit was €28 million, with adjusted net profit of €29.6 million and adjusted diluted EPS of €0.11, up 10%. The company ended the quarter with €111.7 million in cash, €337.7 million in net debt, generated €5.5 million of free cash flow, and maintained full-year 2026 guidance for revenue of €1.260–€1.290 billion, adjusted EBITDA of €331.8–€346.9 million, and adjusted diluted EPS of €0.59–€0.63.
Stevanato Group S.p.A. Schedule 13G reports that Baron Capital Group entities and Ronald Baron beneficially own 2,500,438 ordinary shares, representing 5.03% of the class as reported. The filing attributes shared voting and dispositive power over these shares to the reporting persons.
The filing lists related entities including BAMCO, Inc. with 2,158,466 shares (4.34%) and Baron Capital Management, Inc. with 341,972 shares (0.69%). The advisory clients of BAMCO and BCM are noted as account holders for whom these firms exercise advisory authority.
Stevanato Group SpA amendment to a Schedule 13G/A reports that T. Rowe Price Investment Management, Inc. beneficially owns 3,224,908 shares of common stock, representing 6.5% of the class. The filing lists sole voting and dispositive power over these shares and includes a formal disclaimer denying beneficial ownership.
Stevanato Group has called an ordinary and extraordinary shareholders’ meeting for May 26, 2026 to approve 2025 results, a cash dividend, board elections, auditor appointment, a renewed share repurchase authorization, and bylaw amendments.
The Board proposes approving 2025 standalone net profit of Euro 13,530,074 and distributing a gross cash dividend of Euro 0.054 per outstanding Class A and ordinary share, totaling Euro 14,742,199 using all 2025 profits plus Euro 1,212,126 from reserves, assuming 29,838,842 treasury Class A shares. PwC is proposed as external auditor for 2026–2028 with annual fees of Euro 916,700 for 2026 and Euro 747,300 for 2027–2028. Directors’ and Audit Committee compensation levels from 2025 are proposed to be confirmed. The Board also seeks renewal of authority for one year to purchase and use treasury shares within Italian law limits and up to 20% of share capital, and to amend bylaws on proxy mechanics for beneficial owners, board slate nominations, and Audit Committee composition. A 2025 Sustainability Report highlights progress on emissions (including Scope 3), waste recovery, inclusion and governance, and improved ESG ratings.
Stevanato Group S.p.A. reported higher results for the three months ended March 31, 2026. Revenue rose to EUR 273.6 million from EUR 256.6 million, driven mainly by biopharmaceutical and diagnostic solutions and modest growth in engineering activities.
Operating profit increased to EUR 38.7 million and net profit reached EUR 28.0 million, with basic and diluted EPS steady at EUR 0.10. Strong foreign currency translation gains and cash flow hedges lifted total comprehensive income to EUR 43.1 million, compared with EUR 10.6 million a year earlier.
Cash flow from operations was EUR 75.5 million, largely funding heavy capital expenditures of EUR 70.4 million focused on new facilities in Fishers, Indiana and Latina, Italy. Net working capital investments increased inventories ahead of expected future deliveries. The effective tax rate rose to 28.6% after the end of a prior Italian tax benefit and a precautionary EUR 0.4 million tax provision.
Stevanato Group reported Q1 2026 results showing steady growth and margin improvement while reiterating its full-year 2026 outlook. Revenue rose to €274 million from €257 million, with constant-currency growth of about 10%. High-Value Solutions climbed 17% to €129 million, representing 47% of total revenue, driven by strong demand for pre-fillable syringes and other containment products, including GLP1-related therapies accounting for roughly 21%–22% of revenue.
Biopharmaceutical and Diagnostic Solutions revenue increased 13% to €249 million, while the Engineering segment declined 31% to €24.6 million but improved margins. Gross margin improved to 27.5% and operating margin to 14.2%. Net profit reached €28 million, or €0.10 diluted EPS, and adjusted EBITDA grew 14% to €65 million with a 23.9% margin. The company generated €5.5 million of free cash flow despite €67.6 million of capex and ended the quarter with €111.7 million of cash and €337.7 million of net debt. Management reaffirmed 2026 guidance for revenue of €1.26–€1.29 billion and adjusted EBITDA of €331–€346 million, targeting mid‑single to low‑double‑digit growth.
Stevanato Group reported solid first-quarter 2026 results with revenue up 7% year-over-year (10% at constant currency) to €273.6 million. Growth was driven by the Biopharmaceutical and Diagnostic Solutions segment, where revenue rose 13% to €249.0 million, offsetting a 31% decline in the Engineering segment to €24.6 million.
High-value solutions revenue increased 17% to €128.6 million, representing 47% of total revenue. Gross profit margin improved to 27.5% and operating profit margin to 14.2%. Net profit was €28.0 million, or €0.10 per diluted share, while adjusted net profit reached €29.6 million and adjusted diluted EPS €0.11.
Adjusted EBITDA rose to €65.5 million, with margin expanding to 23.9%. The company generated €5.5 million of free cash flow on €67.6 million of CAPEX and ended March 31, 2026 with net debt of €337.7 million. Management maintained full-year 2026 guidance, including revenue of €1.26–€1.29 billion and adjusted diluted EPS of €0.59–€0.63.
Stevanato Group S.p.A. director Luciano Santel filed an initial ownership report showing a holding of ordinary shares. The filing lists that he directly owns 1,787 ordinary shares of Stevanato Group following the reported position.
This is an initial disclosure of holdings, not a buy or sell transaction, and no option or derivative positions are reported.
Stevanato Group S.p.A. director Elisabetta Magistretti filed an initial ownership report on Form 3 for the company’s ordinary shares, traded under ticker STVN. This filing establishes her status as an insider but does not report any share purchases, sales, or other transactions.
Stevanato Group S.p.A. director Karen Flynn filed an initial ownership report showing she holds 2,275 Ordinary Shares of the company. These shares are reported as held directly, and the filing does not reflect any recent purchase or sale, only her current stake.